Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma

Brief description of study

The primary purpose is to determine the effectiveness and tolerability of eliminating therapy as the initial approach for infants <12 months of age and <18 months of age with small I NRG Stage L 1 neuroblastoma and localized neuroblastoma. We want to know if modification of therapy will produce favorable treatment outcomes. The goal of the study is to treat non-high-risk neuroblastoma (NBL} by either not doing surgery or by changing the amount of chemotherapy given.

Clinical Study Identifier: s18-01776
ClinicalTrials.gov Identifier: NCT02176967

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.